Shaun Chilton, CEO of () tells Proactive that agreement with Bristol-Myers Squibb proves two things.
“One, that pharmaceutical companies, even the biggest ones, are looking to partner in certain parts of the world in terms of commercialising their medicines,“ Shaun Chilton said.
He added: “And also I think it proves that we have built an infrastructure particularly in Africa, using South Africa as a hub, that makes it a very attractive partner to pharmaceutical companies.”
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Clinigen Group PLC named herein, including the promotion by the Company of Clinigen Group PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE